<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20160812029310N4</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2018-07-01</date_registration>
      <primary_sponsor>Esfahan University of Medical Sciences</primary_sponsor>
      <public_title>Effect of Ketofol  and Fenofol on sedation and analgesia</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of Propofol and Ketamine Combination (Ketofol) and Propofol and Fentanyl combination (Fenofol) on sedation and analgesia  in patients undergoing lumpectomy</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2017-02-28</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>64</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/31669</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Other, Randomization description: Patients were randomly assigned to the two groups of Fenofol and Ketofol using random number table, Blinding description: All drugs are prepared and placed at the same volume and homogeneously into the syringes by the investigator. The hemodynamic changes (after the administration of each drug) are monitored and recorded. Moreover, the Participant, Care provider, Outcome assessor, and Data analyser are not aware of the drug type and the investigator will decipher the codes after data analysis.</study_design>
      <phase>2</phase>
      <hc_freetext>Condition 1: sedation. Condition 2: analgesia.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1: Initially, personal consent is obtained from the patients. Then the patient is placed on the operating bed and attached standard monitoring devices including pulsoximetry, capnography, and electrocardiogram. Baseline vital signs are recorded and the drugs are administered firstly through bolus injection and after that through continuous infusion. In this group, propofol (manufactured by B.Braun company  Germany) at the dose of 1 mg/kg plus ketamine (manufactured by Rotexmedica Germany) at the dose of 1 mg/kg are infused during 10 minutes. Mean blood pressure, heart rate and oxygen saturation are recorded 1, 3, 5, 10, 60 and 120 minutes after induction. Intervention 2: Intervention group 2: Initially, personal consent is obtained from the patients. Then the patient is placed on the operating bed and attached standard monitoring devices including pulsoximetry, capnography, and electrocardiogram. Baseline vital signs are recorded and the drugs are administered firstly through bolus injection and after that through continuous infusion. In this group, propofol (manufactured by B.Braun company Germany) at the dose of 1 mg/kg plus Fentanyl (manufactured by Rotexmedica Germany) at the dose of 1mcg/kg are infused during 10 minutes. Mean blood pressure, heart rate and oxygen saturation during 1, 3, 5, 10 minutes after induction and at 60 and 120 minutes are recorded.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Only registered symptoms can be published without mentioning the names of the participants.

When:
"Starting the access period 6 months after printing results"

To whom:
Only available to scholars working in academia and academia

Conditions:
Written request via email and university approval

Where to obtain:
By contacting  corresponding author

How to obtain:
After the email is received by the applicant, it takes one week to agree
   The university will be obtained and then will be notified to the requestor. Maximum of this process takes ten days.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Behzad Nazemroaya</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Ostandari</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8146713543</zip>
        <telephone>+98 31 3224 7233</telephone>
        <email>behzad_nazem@med.mui.ac.ir</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Behzad Nazemroaya</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Ostandari</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8146713543</zip>
        <telephone>+98 31 3224 7233</telephone>
        <email>behzad_nazem@med.mui.ac.ir</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>The patients at the age of 15-70 years old
ASAIII
With breast cancer
ASA I,II
candidates for lumpectomy</inclusion_criteria>
      <agemin>15 years</agemin>
      <agemax>70 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Difficult airway management
mental disorder
allergy to drugs
head Injury
Severe cardiovascular disease
Severe pulmonary disease
history of Epilepsy or  Seizure</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1: Initially, personal consent is obtained from the patients. Then the patient is placed on the operating bed and attached standard monitoring devices including pulsoximetry, capnography, and electrocardiogram. Baseline vital signs are recorded and the drugs are administered firstly through bolus injection and after that through continuous infusion. In this group, propofol (manufactured by B.Braun company  Germany) at the dose of 1 mg/kg plus ketamine (manufactured by Rotexmedica Germany) at the dose of 1 mg/kg are infused during 10 minutes. Mean blood pressure, heart rate and oxygen saturation are recorded 1, 3, 5, 10, 60 and 120 minutes after induction.</i_keyword>
      <i_keyword>Intervention group 2: Initially, personal consent is obtained from the patients. Then the patient is placed on the operating bed and attached standard monitoring devices including pulsoximetry, capnography, and electrocardiogram. Baseline vital signs are recorded and the drugs are administered firstly through bolus injection and after that through continuous infusion. In this group, propofol (manufactured by B.Braun company Germany) at the dose of 1 mg/kg plus Fentanyl (manufactured by Rotexmedica Germany) at the dose of 1mcg/kg are infused during 10 minutes. Mean blood pressure, heart rate and oxygen saturation during 1, 3, 5, 10 minutes after induction and at 60 and 120 minutes are recorded.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Mean arterial pressure. Timepoint: Before and after the intervention, one, three, five, ten minutes after induction of anesthesia and then at 60 and 120 minutes. Method of measurement: Non invasive blood pressure Automated.</prim_outcome>
      <prim_outcome>Heart rate. Timepoint: Before and after the intervention, 1, 3, 5, 10 minutes after induction of anesthesia and then at 60 and 120 minutes. Method of measurement: Pulse oximetry device.</prim_outcome>
      <prim_outcome>Arterial oxygen saturation. Timepoint: Before and after the intervention, 1, 3, 5, 10 minutes after induction of anesthesia and then at 60 and 120 minutes. Method of measurement: Pulse oximetry device.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Intensity of pain. Timepoint: At times 1, 3, 5, 10 minutes after induction of anesthesia and then at 60 and 120 minutes after induction of anesthesia. Method of measurement: Using criterion VAS.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Esfahan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2017-06-28</approval_date>
        <contact_name>Ethics committee of Isfahan University of Medical Sciences</contact_name>
        <contact_address>Isfahan University of Medical Sciences, Hezar jarib street, Azadi square, Isfahan Isfahan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
